Literature DB >> 23321335

Pure white cell aplasia induced by mesalazine in a patient with ulcerative colitis.

Francesco Frattini1, Silvia Crestani, Pier Paolo Vescovi, Massimo Franchini.   

Abstract

UNLABELLED: Objectives and importance: Mesalazine is a widely used and generally safe drug for the treatment of chronic inflammatory bowel diseases. Neutropenia rarely complicates this treatment and very few cases have been reported in the literature. CLINICAL
PRESENTATION: We report here the case of a patient with ulcerative colitis who developed a severe febrile neutropenia during treatment with mesalazine. INTERVENTION: Drug withdrawal and treatment with granulocyte colony-stimulating factor resulted in a complete and durable remission of cytopenia. Conclusion headings: We recommend periodic blood count monitoring in all patients undergoing treatment with mesalazine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23321335     DOI: 10.1179/1607845412Y.0000000043

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  4 in total

1.  Pure white cell aplasia: report of first case associated with autoimmune hepatitis.

Authors:  Thomas Keast; Deshan Weeraman; Phil Mayhead; Richard Grace; Stamford Mathe
Journal:  Frontline Gastroenterol       Date:  2014-03-25

Review 2.  Five-aminosalicylic Acid: an update for the reappraisal of an old drug.

Authors:  Cristiana Perrotta; Paolo Pellegrino; Eliana Moroni; Clara De Palma; Davide Cervia; Piergiorgio Danelli; Emilio Clementi
Journal:  Gastroenterol Res Pract       Date:  2015-01-21       Impact factor: 2.260

3.  A Rare Complication of Thymoma: Pure White Cell Aplasia in Good's Syndrome.

Authors:  Kim Uy; Elizabeth Levin; Pawel Mroz; Faqian Li; Surbhi Shah
Journal:  Case Rep Hematol       Date:  2019-10-13

4.  Pure White Cell Aplasia Complicated by Systemic Sclerosis with Accompanying Scleroderma Renal Crisis.

Authors:  Eiji Suzuki; Ryoma Oda; Takashi Kanno; Satoru Kimura; Yurie Saito; Hiroyuki Kanbayashi; Shin Matsuda; Kiyoshi Migita
Journal:  Intern Med       Date:  2021-11-20       Impact factor: 1.282

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.